Daily Insider Ratings Report: Jan 18, 2018
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research processAlimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. The company's commercial product is ILUVIEN?, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. The company commercially markets ILUVIEN in the United States, Germany, the United Kingdom, Portugal, Austria and Ireland. The company has three segments: the United States, International and Other.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.